other material
confidence high
sentiment positive
materiality 0.45
Moleculin: Annamycin plus PD-1 blockade extends survival in pancreatic cancer preclinical models
Moleculin Biotech, Inc.
- In an immunocompetent KPC mouse model of advanced pancreatic ductal adenocarcinoma, liposomal Annamycin (L-ANN) plus PD-1 blockade increased survival vs either agent alone; reconfirmed independently.
- Annamycin reached substantially higher and more sustained pancreatic tissue exposure than doxorubicin at the same dose, with increased CD8+ cytotoxic and CD4+ helper T-cell infiltration.
- Depleting CD8+ T cells shortened survival in treated mice, showing the immune system contributes to Annamycin's antitumor activity rather than being a bystander.
- Data presented Nov 10, 2026 by Waldemar Priebe, PhD of MD Anderson at the Marie Sklodowska-Curie Symposium in Tampa, building on AACR April and September 2026 results.
- CEO Walter Klemp said the priority remains the MIRACLE AML trial with a Q1 2027 data readout; Moleculin plans to sponsor an investigator-initiated pancreatic cancer trial in 2027.